glp-1 gip therapies muscle preservation combination 2025 and health: Beyond weight loss in the Ozempic era Optimizing GLP-1 therapies for obesity

& Klaphajone, J

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

California health officials said Medi-Cal members and their health care providers should consider other treatment options that can support weight loss, such as diet changes, increased activity or exercise, and counseling. That echoes advice from the New Hampshire Medicaid program

Pape VFS, Trk D, Szab P, Wiese M, Enyedy EA, Szakcs G

Vascular and neurodegenerative disorders in T2D may involve the same pathways such as hyperglycemia, altered insulin signaling, severe low-grade inflammation, and AGE to cause neurocognitive decline

For many women, the issue is not simply lack of willpower. The picture is usually far more complex